Session 3: Successful Drug Development Stories and Learnings
Chairs: Venkatesh Pilla Reddy, AstraZeneca, and Jaydeep Yadav, Merck Research Laboratories
Recent IQ PBPK Induction Survey Outcome and Current Status
  
 Tammie Cabalu, Merck & Co., Inc, Philadelphia, Pennsylvania, USA
PBPK Joins PMX in fight of COVID-19 Therapeutics
  
 Pradeep Sharma, AstraZeneca, Cambridge, United Kingdom
PBPK Case Studies for Regulatory Submissions Including Consultant Examples
  
 Karen Rowland Yeo, Certara, Sheffield, United Kingdom
Recent Examples of PBPK from FDA and Implementation of Verification/validation in Reviewing PBPK Submissions
  
 Jianghong Fan, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
Effect of a Ketohexokinase Inhibitor (PF-06835919) on in vivo OATP1B Activity 
  
 Emi Kimoto, Pfizer, Inc, Groton, Connecticut, USA
Selected Abstract Presentation: P7. THE APPLICATION OF MACHINE LEARNING IN THE PREDICTION OF DRUG-DRUG INTERACTIONS
Jaidip Gill, Imperial College London, London, United Kingdom
Roundtable Discussion with Speakers